ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

OPNT Opiant Pharmaceuticals Inc

20.65
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Opiant Pharmaceuticals Inc NASDAQ:OPNT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 20.65 18.89 22.41 0 01:00:00

Opiant Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021

22/07/2021 9:05pm

GlobeNewswire Inc.


Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Opiant Pharmaceuticals Charts.

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the second quarter ended June 30, 2021, after the financial markets close on Thursday, August 5, 2021.

The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday, August 5, 2021. To access the call, please dial 888-394-8218 in the U.S. or 323-794-2588 outside the U.S. and provide the conference ID number: 5960603. To access the live webcast, please visit http://public.viavid.com/index.php?id=145669. Following the live webcast, an archived version of the call will be available on the website.

Thursday August 5 @ 4:30 pm ET

Domestic:888-394-8218
International:323-794-2588
Conference ID:5960603
Webcast:http://public.viavid.com/index.php?id=145669

About Opiant Pharmaceuticals, Inc.Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com.

For Media and Investor Inquiries:Ben Atkins, Opiant(310) 598-5410batkins@opiant.com

1 Year Opiant Pharmaceuticals Chart

1 Year Opiant Pharmaceuticals Chart

1 Month Opiant Pharmaceuticals Chart

1 Month Opiant Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock